RNXT
RenovoRx, Inc.
Price Chart
Latest Quote
$0.92
+0.03 (+3.29%)
Current Price
| Previous Close | $0.89 |
| Open | $0.91 |
| Day High | $0.94 |
| Day Low | $0.89 |
| Volume | 302,967 |
Stock Information
| Shares Outstanding | 45.10M |
| Total Debt | $186K |
| Cash Equivalents | $12.36M |
| Revenue | $1.49M |
| Net Income | $-12.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $41.49M |
| EPS (TTM) | $-0.34 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $29.32M |
| Sales | $1.49M |
| Income | $-12.27M |
| Book/sh | $0.25 |
| Cash/sh | $0.27 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 6.58 |
| Current Ratio | 7.15 |
| Debt/Eq | 1.65 |
Returns & Margins
| ROA | -51.58% |
| ROE | -100.48% |
| Gross Margin | 78.71% |
| Operating Margin | -616.16% |
Ownership
| Insider Ownership | 3.77% |
| Institutional Ownership | 19.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.13 |
| P/S | 27.87 |
| P/B | 3.68 |
Analyst Data
| Recommendation | none |
| Target Price | $7.03 |
Technical Indicators
| SMA20 | $0.90 |
| SMA50 | $0.90 |
| SMA200 | $0.99 |
| RSI | 51.48 |
| ATR | 0.0595 |
| Shares Float | 39.87M |
| Short Float | 0.95% |
| Short Ratio | 1.38 |
| Volatility | 1.00 |
| Rel Volume | 1.06 |
Performance History
| Week | +6.36% |
| Month | +14.14% |
| Quarter | -8.91% |
| 6 Months | +9.13% |
| YTD | +10.18% |
| Year | -31.85% |
| 3 Years | -50.54% |
| 10 Years | -87.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.92 | 330,600 |
| 2026-06-17 | $0.89 | 137,900 |
| 2026-06-16 | $0.88 | 83,900 |
| 2026-06-15 | $0.89 | 173,800 |
| 2026-06-12 | $0.84 | 129,600 |
| 2026-06-11 | $0.87 | 262,600 |
| 2026-06-10 | $0.85 | 226,500 |
| 2026-06-09 | $0.86 | 166,600 |
| 2026-06-08 | $0.89 | 429,600 |
| 2026-06-05 | $0.87 | 326,000 |
| 2026-06-04 | $0.98 | 525,300 |
| 2026-06-03 | $0.91 | 332,000 |
| 2026-06-02 | $0.91 | 244,300 |
| 2026-06-01 | $0.92 | 551,400 |
| 2026-05-29 | $0.91 | 317,400 |
| 2026-05-28 | $0.99 | 699,700 |
| 2026-05-27 | $0.93 | 226,800 |
| 2026-05-26 | $0.92 | 433,000 |
| 2026-05-22 | $0.88 | 162,600 |
| 2026-05-21 | $0.88 | 489,200 |
| 2026-05-20 | $0.81 | 127,700 |
| 2026-05-19 | $0.81 | 273,900 |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
đ° Latest News
RenovoRx, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T12:30:00Z
RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion
GuruFocus.com âĸ 2026-05-15T05:01:58ZRenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-14T21:30:03Z
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Zacks âĸ 2026-05-07T21:55:02Z
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks âĸ 2026-05-07T14:00:04Z
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-06T21:25:08Z
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-05T22:05:07Z
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com âĸ 2026-03-31T03:01:11ZBiorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-26T22:25:02Z
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-24T21:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $327,000 | $0 | $0 | - |
| Cost Of Revenue | $327,000 | $0 | $0 | - |
| Total Revenue | $1,123,000 | $43,000 | $0 | $0 |
| Operating Revenue | $1,123,000 | $43,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $13,634,000 | $11,013,000 | $11,396,000 | $9,950,000 |
| Other Income Expense | $915,000 | $1,772,000 | $1,709,000 | $4,000 |
| Net Non Operating Interest Income Expense | $427,000 | $384,000 | $-545,000 | $57,000 |
| Operating Expense | $13,307,000 | $11,013,000 | $11,396,000 | $9,950,000 |
| General And Administrative Expense | $7,038,000 | $4,988,000 | $5,729,000 | $5,649,000 |
| Total Other Finance Cost | - | $-384,000 | $545,000 | $-57,000 |
| Other Non Operating Income Expenses | - | - | - | $4,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Net Interest Income | $427,000 | $384,000 | $-545,000 | $57,000 |
| Interest Income | $427,000 | $384,000 | - | $57,000 |
| Normalized Income | $-12,083,000 | $-10,586,000 | $-11,941,000 | $-9,889,000 |
| Net Income From Continuing And Discontinued Operation | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Total Operating Income As Reported | $-12,510,000 | $-10,970,000 | $-11,396,000 | $-9,950,000 |
| Net Income Common Stockholders | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Net Income | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Net Income Including Noncontrolling Interests | $-11,169,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Net Income Continuous Operations | $-11,169,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Pretax Income | $-11,169,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Interest Income Non Operating | $427,000 | $384,000 | - | $57,000 |
| Operating Income | $-12,511,000 | $-10,970,000 | $-11,396,000 | $-9,950,000 |
| Gross Profit | $796,000 | $43,000 | $0 | - |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.32 | $-0.40 | $-0.99 | $-1.09 |
| Basic EPS | $-0.32 | $-0.40 | $-0.99 | $-1.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,424,000 | $-12,742,000 | $-13,105,000 | $-9,944,000 |
| Total Unusual Items | $915,000 | $1,772,000 | $1,709,000 | $0 |
| Total Unusual Items Excluding Goodwill | $915,000 | $1,772,000 | $1,709,000 | $0 |
| Reconciled Depreciation | $2,000 | $0 | $0 | $6,000 |
| EBITDA (Bullshit earnings) | $-12,509,000 | $-10,970,000 | $-11,396,000 | $-9,944,000 |
| EBIT | $-12,511,000 | $-10,970,000 | $-11,396,000 | $-9,950,000 |
| Diluted Average Shares | $35,333,127 | $22,271,163 | $10,290,667 | $9,051,726 |
| Basic Average Shares | $35,333,127 | $22,271,163 | $10,290,667 | $9,051,726 |
| Diluted NI Availto Com Stockholders | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Gain On Sale Of Security | $915,000 | $1,772,000 | $1,709,000 | - |
| Research And Development | $6,269,000 | $6,025,000 | $5,667,000 | $4,301,000 |
| Selling General And Administration | $7,038,000 | $4,988,000 | $5,729,000 | $5,649,000 |
| Other Gand A | $3,768,000 | $2,297,000 | $3,261,000 | $3,733,000 |
| Salaries And Wages | $3,270,000 | $2,691,000 | $2,468,000 | $1,916,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Total Assets | $8,095,000 | $8,118,000 | $1,466,000 | $7,265,000 |
| Total Non Current Assets | $202,000 | $290,000 | $0 | $0 |
| Current Assets | $7,893,000 | $7,828,000 | $1,466,000 | $7,265,000 |
| Other Current Assets | $217,000 | $303,000 | $24,000 | $825,000 |
| Prepaid Assets | $324,000 | $328,000 | $168,000 | - |
| Inventory | $189,000 | $0 | - | - |
| Receivables | $139,000 | $43,000 | $0 | - |
| Accounts Receivable | $139,000 | $43,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $7,024,000 | $7,154,000 | $1,173,000 | $6,440,000 |
| Cash And Cash Equivalents | $7,024,000 | $7,154,000 | $1,173,000 | $4,391,000 |
| Current Deferred Assets | - | $0 | $101,000 | $0 |
| Non Current Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $212,000 | $278,000 | $0 | - |
| Long Term Debt And Capital Lease Obligation | $107,000 | $212,000 | $0 | - |
| Current Debt And Capital Lease Obligation | $105,000 | $66,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,673,000 | $3,640,000 | $4,466,000 | $1,102,000 |
| Total Non Current Liabilities Net Minority Interest | $711,000 | $1,731,000 | $3,291,000 | $0 |
| Derivative Product Liabilities | $604,000 | $1,519,000 | $3,291,000 | $0 |
| Current Liabilities | $1,962,000 | $1,909,000 | $1,175,000 | $1,102,000 |
| Payables And Accrued Expenses | $1,109,000 | $1,026,000 | $1,100,000 | $627,000 |
| Payables | $799,000 | $586,000 | $561,000 | $534,000 |
| Accounts Payable | $799,000 | $586,000 | $561,000 | $534,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Total Equity Gross Minority Interest | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Stockholders Equity | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Retained Earnings | $-61,387,000 | $-50,219,000 | $-41,405,000 | $-31,173,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $0 | $17,000 |
| Other Equity Adjustments | - | - | - | $17,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $36,613,916 | $24,034,672 | $10,693,580 | $9,097,701 |
| Share Issued | $36,613,916 | $24,034,672 | $10,693,580 | $9,097,701 |
| Tangible Book Value | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Invested Capital | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Working Capital | $5,931,000 | $5,919,000 | $291,000 | $6,163,000 |
| Capital Lease Obligations | $212,000 | $278,000 | $0 | - |
| Total Capitalization | $5,422,000 | $4,478,000 | $-3,000,000 | $6,163,000 |
| Additional Paid In Capital | $66,805,000 | $54,695,000 | $38,404,000 | $37,318,000 |
| Capital Stock | $4,000 | $2,000 | $1,000 | $1,000 |
| Common Stock | $4,000 | $2,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $107,000 | $212,000 | $0 | - |
| Current Capital Lease Obligation | $105,000 | $66,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $748,000 | $817,000 | $75,000 | $475,000 |
| Current Accrued Expenses | $310,000 | $440,000 | $539,000 | $93,000 |
| Net PPE | $202,000 | $290,000 | $0 | $0 |
| Accumulated Depreciation | $-2,000 | $0 | $0 | - |
| Gross PPE | $204,000 | $290,000 | $0 | $0 |
| Other Properties | $190,000 | $278,000 | - | - |
| Machinery Furniture Equipment | $14,000 | $12,000 | $0 | - |
| Finished Goods | $189,000 | $0 | - | - |
| Other Short Term Investments | - | - | $0 | $2,049,000 |
| Leases | - | - | - | $0 |
| Properties | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,975,000 | $-9,137,000 | $-10,258,000 | $-8,811,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,973,000 | $-9,125,000 | $-10,258,000 | $-8,811,000 |
| Cash Flow From Continuing Operating Activities | $-10,973,000 | $-9,125,000 | $-10,258,000 | $-8,811,000 |
| Operating Gains Losses | $-915,000 | $-1,772,000 | $-1,709,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,000 | $-12,000 | - | - |
| Investing Cash Flow | $-2,000 | $-12,000 | $2,032,000 | $-2,032,000 |
| Cash Flow From Continuing Investing Activities | $-2,000 | $-12,000 | $2,032,000 | $-2,032,000 |
| Capital Expenditure Reported | - | - | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,102,000 | $17,248,000 | $5,000,000 | $0 |
| Financing Cash Flow | $10,845,000 | $15,118,000 | $5,008,000 | $42,000 |
| Cash Flow From Continuing Financing Activities | $10,845,000 | $15,118,000 | $5,008,000 | $42,000 |
| Net Other Financing Charges | $-1,299,000 | $-2,232,000 | - | - |
| Net Common Stock Issuance | $12,102,000 | $17,248,000 | $5,000,000 | $0 |
| Common Stock Issuance | $12,102,000 | $17,248,000 | $5,000,000 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $16,000 | $21,000 | $14,000 | - |
| Income Tax Paid Supplemental Data | $1,000 | $2,000 | $38,000 | - |
| End Cash Position | $7,024,000 | $7,154,000 | $1,173,000 | $4,391,000 |
| Beginning Cash Position | $7,154,000 | $1,173,000 | $4,391,000 | $15,192,000 |
| Changes In Cash | $-130,000 | $5,981,000 | $-3,218,000 | $-10,801,000 |
| Proceeds From Stock Option Exercised | $42,000 | $102,000 | $8,000 | $42,000 |
| Net PPE Purchase And Sale | $-2,000 | $-12,000 | $0 | - |
| Purchase Of PPE | $-2,000 | $-12,000 | $0 | - |
| Change In Working Capital | $-247,000 | $280,000 | $605,000 | $428,000 |
| Change In Other Current Assets | $0 | $-221,000 | $-101,000 | $9,000 |
| Change In Payables And Accrued Expense | $-52,000 | $661,000 | $73,000 | $155,000 |
| Change In Accrued Expense | $-265,000 | $636,000 | $46,000 | $155,000 |
| Change In Payable | $213,000 | $25,000 | $27,000 | $9,000 |
| Change In Account Payable | $213,000 | $25,000 | $27,000 | $0 |
| Change In Prepaid Assets | $90,000 | $-160,000 | $633,000 | $264,000 |
| Change In Inventory | $-189,000 | $0 | - | - |
| Change In Receivables | $-96,000 | $0 | - | - |
| Changes In Account Receivables | $-96,000 | $0 | - | - |
| Other Non Cash Items | $88,000 | $7,000 | - | - |
| Stock Based Compensation | $1,267,000 | $1,174,000 | $1,078,000 | $644,000 |
| Depreciation Amortization Depletion | $2,000 | $0 | $0 | $6,000 |
| Depreciation And Amortization | $2,000 | $0 | $0 | $6,000 |
| Depreciation | $2,000 | $0 | $0 | $6,000 |
| Gain Loss On Investment Securities | $-915,000 | $-1,772,000 | $-1,709,000 | - |
| Net Income From Continuing Operations | $-11,168,000 | $-8,814,000 | $-10,232,000 | $-9,889,000 |
| Net Investment Purchase And Sale | - | $0 | $2,032,000 | $-2,032,000 |
| Sale Of Investment | - | $0 | $2,032,000 | $5,968,000 |
| Purchase Of Investment | - | - | $0 | $-8,000,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Change In Interest Payable | - | - | - | - |
Fetched: 2026-06-17